Minoxidil for androgenetic alopecia: when to assess and when to stop?

Androgenetic alopecia (AGA) is the most common form of progressive hair loss. Minoxidil has been one of the leading first-line treatments for androgenetic alopecia for decades.^1,3,6 However, patients and healthcare providers often assess the efficacy of minoxidil too early, which can lead to premature discontinuation.² This article discusses when a response can realistically be expected and at what point the treatment can justifiably be considered ineffective.

Time to clinical effect

Minoxidil prolongs the anagen phase and increases follicular volume, but these biological effects do not translate into clinically visible results until months later.^2,3 In clinical studies and reviews of AGA, improvement is typically seen in months 3–12 of treatment.^1,3,6 Clinically, three levels can be distinguished:

• First subtle growth: often fine, vellus hairs after about 2–3 months of consistent use.^1,2
• Cosmetically noticeable improvement: on average after 3–6 months, depending on severity, location, and degree of miniaturization.^1,2 In some patients, the response may be slower, and a clear benefit may sometimes not become visible until after 9–12 months.^2,5
• Full effect assessment: ideally after approximately 12 months of continuous use.^2,3

In the first few weeks, a temporary increase in hair loss (“shedding”) may occur, because telogen hairs fall out at an accelerated rate before a new anagen cycle starts.³ This is a physiological and usually temporary phenomenon, not a sign of treatment failure.³ Discontinuing treatment too early, for example after three months without change, can therefore lead to a “false negative” judgment regarding efficacy.

Criteria for a non-responder

A patient can only be considered a non-responder when three basic conditions are met:

1. Correct indication: the clinical picture is consistent with AGA; other forms, such as scarring alopecia or pure telogen effluvium, are excluded.
2. Correct dosage: topical 5% once to twice daily (men) or 2–5% (women); for off-label low-dose oral minoxidil (LDOM) usually <5 mg/day, adjusted for sex and comorbidities.^2,4
3. Good adherence to therapy: demonstrable daily use for at least 6 months, preferably 12 months, without frequent interruptions.²

If clinical improvement fails to occur after 6–12 months under these conditions, it is justified to consider the effect insufficient.^2,3,6 In consultation with the patient, consideration may then be given to discontinuing treatment or combining it with other therapies, such as finasteride (men), dutasteride (off-label), LDOM (off-label), PRP, or hair transplantation.^2,4

Treatment evaluation

An objective assessment requires structured follow-up. In practice, three pillars are useful:

• Photographic documentation at baseline, after 3, 6, and 12 months, with standardized lighting and camera angle.
• Clinical or dermatoscopic assessment of density and hair caliber as early markers of response.³
• Counseling before and during treatment: explanation of delayed effect assessment, possible early shedding, and the need to continue treatment to maintain effect.^2,3

After discontinuation of minoxidil, loss of the achieved effect usually occurs; hair status returns within a few months to the expected baseline level without treatment.^2,3,4

When to stop?

Side effects are relatively rare, but may warrant earlier discontinuation. Topical minoxidil can cause contact dermatitis, irritation, or itching.² Systemic side effects, such as edema, hypotension, or tachycardia, are mainly seen with oral administration at higher doses, but have also been described at low doses.^2,4

Stopping is particularly advisable in the event of:

• persistent or severe local irritation or allergic contact dermatitis despite adjustment of vehicle or frequency.²
• systemic complaints likely related to minoxidil use, after assessment of cardiovascular status.^2,4
• absence of relevant clinical effect after at least 12 months of correct application, provided that indication and adherence have been carefully verified.^2,3

In the absence of side effects, it is generally sensible to continue treatment for at least 6 months and preferably 12 months before concluding non-response.²

Practical recommendations

• Do not assess the efficacy of minoxidil before 6 months and schedule a definitive evaluation around 12 months.^2,3,6
• Explain at the start that initial shedding may occur and is usually temporary.³
• Use standardized photos to make subtle gains visible, also to the patient.²
• Consider other or additional therapies only when indication, dosage, and adherence are convincingly correct and there is no clinically relevant effect after 6–12 months.^2,4

By setting realistic expectations and using a fixed evaluation structure, premature discontinuation of minoxidil can be prevented, and the likelihood increases that patients who may benefit will continue therapy for a sufficiently long period.²

Minoxidil evaluation scheme for androgenetic alopecia

The table below summarizes when effect should be assessed and when stopping is justifiable.

References

1. Olsen EA, Weiner MS, DeLong ER, Pinnell SR. Topical minoxidil in early male pattern baldness. J Am Acad Dermatol. 1985;13(2 Pt 1):185–192.
2. Devjani S, Ezemma O, Kelley KJ, Stratton E, Senna MM. Androgenetic alopecia: therapy update. Drugs. 2023;83:701–715.
3. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186–194.
4. Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777–2786.
5. Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6(2):130–136.
6. Van Dongen T. et al. Guidance on androgenetic alopecia and female pattern hair loss. Dutch Society of Dermatology and Venereology (NVDV).